QCG
XLRN

Quadrant Capital Group’s Acceleron Pharma XLRN Stock Holding History

Quadrant Capital Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-37
Closed -$6K – 2790
2021
Q3 		$6K Sell
37
-8
-18% -$1.05K ﹤0.01% 1840
2021
Q2 		$6K Sell
45
-20
-31% -$2.52K ﹤0.01% 1810
2021
Q1 		$9K Buy
65
+39
+150% +$5.04K ﹤0.01% 1573
2020
Q4 		$3K Buy
26
+13
+100% +$1.52K ﹤0.01% 1900
2020
Q3 		$1K Buy
13
+5
+63% +$498 ﹤0.01% 2128
2020
Q2 		$1K Hold
8
– – ﹤0.01% 2182
2020
Q1 		$0 Buy
8
+5
+167% +$389 ﹤0.01% 2339
2019
Q4 		$0 Buy
+3
New +$137 ﹤0.01% 2528
2019
Q2 		– Sell
-1,008
Closed -$46K – 2437
2019
Q1 		$46K Buy
+1,008
New +$44.3K 0.01% 1274

Quadrant Capital Group's XLRN Position: Q4 2021 in Review

Quadrant Capital Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 37 shares — an estimated $6K sold.

Quadrant Capital Group first reported a position in XLRN in Q1 2019 and held it in 9 quarters. The position peaked at $46K in Q1 2019. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Quadrant Capital Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 37 Acceleron Pharma shares in Q4 2021, an estimated $6K.
  • Quadrant Capital Group first reported a position in Acceleron Pharma in Q1 2019 and held it in 9 quarters.
  • Quadrant Capital Group's Acceleron Pharma position peaked at $46K in Q1 2019.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Quadrant Capital Group's 13F filing for Q4 2021, filed 1 Feb 2022.